Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company has put the launch on ice while it waits for the coronavirus pandemic to ...
Robert Burakoff, MD, MPH, is a board-certified gastroenterologist who serves as vice chair of Ambulatory Services at Lower Manhattan Hospital and professor of medicine at the Weill Cornell Medical ...
Abstract: This study aims to utilize Simscape/MATLAB tool potential to investigate the dynamic behavior of an air conditioning system and analyze the effects of many parameters on the performance of ...
Abstract: The increasing adoption of all-electric ships and seaport microgrids has highlighted the critical need for robust and resilient control in shipboard DC microgrids. These islanded systems, ...
Today, a brief rundown of news from Bristol Myers Squibb and Cytokinetics as well as updates from Disc Medicine and Teva Pharmaceutical that you may have missed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results